Summary:
A genomic and transcriptomic study led by the Germans Trias i Pujol Research Institute (IGTP) demonstrates that blood platelets serve as a sensitive window into the molecular progression of Parkinson’s disease. Published in Movement Disorders, researchers tracked longitudinal gene expression in a patient with a rare de novo SNCA gene triplication as the disease advanced to dementia over three years.
Platelets revealed significantly more pronounced transcriptomic alterations, spanning mitochondrial pathways, protein translation, and neuroinflammation, than whole blood. Key alterations, including dysregulation of SNCA, YWHAB (14-3-3), and MMRN1, were corroborated in an independent cohort of patients with sporadic early-onset Parkinson’s.
Key Facts:
- Platelet Sensitivity Over Whole Blood: Platelets captured progression-associated transcriptomic shifts far more clearly than standard whole-blood assays, revealing specific disruptions in mitochondrial respiration, protein synthesis, and inflammatory cascades.
- Tracking a Rare SNCA Triplication: The investigation tracked a rare, non-inherited de novo 2.41-megabase triplication covering 21 genes, comparing transcriptomic profiles at age 41 (early motor phase) and age 44 (onset of dementia).
- Validation in Sporadic Disease: Significant molecular shifts, such as reduced expression of an SNCA RNA isoform and YWHAB (14-3-3 protein family), alongside upregulation of MMRN1, were cross-validated in an independent cohort of 15 sporadic early-onset Parkinson’s patients compared to 18 controls.
Source: Germans Trias i Pujol Research Institute (IGTP)
Tracking the progression of Parkinson’s disease in clinical practice remains notoriously difficult. Because current clinical scales rely on subjective motor and cognitive evaluations, clinicians lack accessible, minimally invasive liquid biomarkers capable of charting neurodegenerative velocity or identifying early transitions toward dementia. While whole-blood transcriptomics has been widely investigated, peripheral immune cells and serum components often produce biological noise that obscures central nervous system dynamics.
Blood platelets (thrombocytes), however, share unexpected biological commonalities with central neurons. They possess regulated secretory granules, metabolize dopamine and serotonin, express high baseline levels of alpha-synuclein, and maintain active mitochondrial networks.
Now, an investigation by the Genomics and Transcriptomics of Synucleinopathies (GTS) research group at the Germans Trias i Pujol Research Institute (IGTP) in Badalona, Spain, indicates that platelets may serve as an accessible peripheral model for tracking Parkinson’s disease progression.
Publishing in the official journal of the International Parkinson and Movement Disorder Society, Movement Disorders, the research team tracked molecular expression patterns across disease stages, uncovering a transcriptomic bridge between rare genetic parkinsonism and everyday sporadic cases.
Insights From a De Novo Gene Triplication
The study was co-led by Katrin Beyer, PhD, head of the GTS research group at IGTP, and Pau Pastor, MD, PhD, a clinical neurologist at Hospital Universitari Germans Trias i Pujol, with predoctoral researcher Susanna Jiménez-Román serving as first author. Collaborators from the Universitat Autònoma de Barcelona and the Josep Carreras Leukaemia Research Institute also contributed to the multi-center project.
The investigation centered around an extraordinary clinical case: a patient presenting with early-onset Parkinson’s disease who experienced a rapid, aggressive transition to dementia within three years. Genetic sequencing revealed a massive, non-inherited (de novo) 2.41-megabase triplication on chromosome 4q22.1 spanning 21 genes, prominently including SNCA, which encodes the toxic aggregate-forming protein alpha-synuclein.
Because the patient was evaluated longitudinally, the research team isolated both whole blood and purified platelet fractions at two defining clinical milestones: at age 41, during early-stage motor symptoms, and at age 44, following the clinical onset of dementia.
Comparing RNA expression across these two time points revealed that while whole-blood samples showed minimal changes, isolated platelets captured a wave of molecular dysregulation. The differentially expressed platelet genes mapped directly to essential pathways:
- Mitochondrial Homeostasis: Impairment of electron transport chain components and cellular bioenergetics.
- Ribosomal Machinery: Widespread alterations in translation factors and protein synthesis.
- Inflammatory Signaling: Shifting cascades linked to systemic and vascular immune activation.
“This exceptional case has allowed us to study how molecular signals evolve as Parkinson’s disease progresses. Platelets show more pronounced changes than whole blood, highlighting their value as an accessible source for investigating potential biomarkers of progression,” explained Susanna Jiménez-Román.
Shared Signatures in Sporadic Parkinson’s
To evaluate whether these transcriptomic changes were idiosyncratic to this rare mutation or representative of broader disease biology, the investigators assessed a targeted panel of candidate genes in an independent validation cohort.
The cohort comprised 15 patients diagnosed with early-onset sporadic Parkinson’s disease (lacking family histories or known monogenic mutations) and 18 matched healthy controls.
Platelet profiling across the sporadic group corroborated multiple key findings observed in the longitudinal case:
- Downregulation of SNCA and YWHAB: Patients exhibited significant downregulation of a specific SNCA transcript variant alongside YWHAB, a gene encoding 14-3-3 protein beta/alpha, an essential chaperone involved in binding alpha-synuclein and regulating cell survival.
- Upregulation of MMRN1: Significant elevation of multimerin-1 (MMRN1), an endothelial and platelet-stored adhesive protein involved in vascular dynamics.
- Protein Synthesis Induction: Elevated expression of two key genes governing ribosomal assembly.
Importantly, after correcting for multiple statistical comparisons, these transcriptomic differences remained significant in purified platelets, whereas analysis of whole blood from the exact same patients yielded no statistically detectable divergence from healthy controls.
Clinical Outlook and Next Steps
The concordance between an aggressive monogenic triplication and typical sporadic cases indicates that rare, high-penetrance genetic mutations can illuminate fundamental pathogenic cascades shared by the broader Parkinson’s population.
“The relevance of this study extends beyond this rare genetic alteration. Some of the molecular signals identified are also present in patients with early-onset sporadic Parkinson’s disease. This suggests that studying rare cases can help us understand shared mechanisms and open up new avenues for investigating disease progression,” Jiménez-Román noted.
The authors caution that because longitudinal sampling was evaluated within a single patient, these findings establish proof-of-concept rather than a clinically validated diagnostic assay.
The GTS group is expanding longitudinal recruitment across diverse sporadic cohorts to verify whether these platelet RNA signatures can forecast cognitive decline or monitor therapeutic efficacy in upcoming disease-modifying clinical trials.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuroscience Research:
- Media Contact: Tamara Gutiérrez
- Source: IGTP
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Movement Disorders (Oct 1, 2026). “Severe Parkinson’s Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report.” Authors: Susanna Jiménez-Román MSc, David Adamuz MSc, Jorge Mena PhD, Abril Tuset BSc, Mar Mallo PhD, Alex Menendez MD, Daniela Samaniego MD, Lourdes Ispierto MD, PhD, Dolores Vilas MD, PhD, Pau Pastor MD, PhD, Katrin Beyer PhD.
- DOI: 10.1002/mds.70529
Abstract
Severe Parkinson’s Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report
Parkinson’s disease (PD) is characterized by α-synuclein aggregation, dopaminergic neurodegeneration, and chronic neuroinflammation. Increasing evidence also supports systemic immune dysregulation, and platelets (PLTs) have emerged as a relevant peripheral model because they share several functional and molecular features with neurons.
